Loading clinical trials...
Loading clinical trials...
CD123-Targeted CD16 Antibody-Modified NK Cell Immunotherapy for Refractory/Relapsed Acute Myeloid Leukemia (R/R AML)
Conditions
Interventions
Donor-derived CD123-CD16 bispecific antibody-modified NK cells
Locations
1
China
Chinese PLA General Hospital
Beijing, China, China
Start Date
February 21, 2025
Primary Completion Date
December 31, 2025
Completion Date
December 31, 2025
Last Updated
February 25, 2025
NCT05475925
NCT06859424
NCT07347171
NCT06911710
NCT06783790
NCT06635681
Lead Sponsor
Chunji Gao
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions